Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Precipio Inc's Business Segments
Precipio Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q2 FY2026
Reportable Segments
1
Largest Segment
Single reportable segment
Total Revenue
$ 7
Regions Reported
-
Revenue Share by Reportable Segment - Q2 FY2026
- Single reportable segment100%
Revenue by Reportable Segment - Q2 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single reportable segment | $ 7 | 100% |
Revenue by Product & Service Category - Q2 FY2026
- Service revenue net87.1%
- Product12.9%
Revenue by Product & Service Category - Q2 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Service revenue net | $ 6 | 87.1% |
| Product | $ 1 | 12.9% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of Precipio Inc
Precipio Inc. is a specialized diagnostic company that provides diagnostic solutions to the healthcare industry. The company focuses on implementing innovative technologies to provide accurate and reliable diagnostic information to healthcare providers and patients.
Precipio Inc. offers a wide range of diagnostic tests and services, including cytology, molecular diagnostics, and hematology. The company's proprietary technologies and methodologies allow for fast and precise results, enabling healthcare providers to make informed decisions for patient care.
One of Precipio's key offerings is its cytology services. Cytology is the study of cells to diagnose diseases, and Precipio provides comprehensive cytology testing for various conditions such as cancers, infections, and autoimmune disorders. The company's team of experienced pathologists and laboratory scientists analyze samples using advanced techniques, ensuring accurate and timely results.
In addition to cytology, Precipio specializes in molecular diagnostics, which involves analyzing DNA and RNA to detect genetic and infectious diseases. By utilizing cutting-edge molecular techniques, the company can identify specific genetic mutations, viruses, and bacteria, aiding doctors in making personalized treatment decisions for patients.
Furthermore, Precipio offers hematology testing services, which focus on analyzing blood samples to diagnose and monitor blood-related disorders like anemia, leukemia, and blood clotting disorders. The company's state-of-the-art equipment and skilled laboratory personnel ensure precise and efficient testing, allowing for prompt diagnosis and appropriate treatment.
To support its diagnostic offerings, Precipio has developed a proprietary software platform called HemeScreen. This cloud-based platform integrates with laboratory information systems and supports the entire diagnostic process, from sample collection to reporting. HemeScreen enhances workflow efficiency, minimizes errors, and provides real-time communication between healthcare providers and laboratory personnel.
Precipio also collaborates with healthcare partners, including hospitals, medical centers, and pharmaceutical companies, to develop customized diagnostic solutions. The company's expertise in molecular diagnostics and cytology enables it to offer a range of services tailored to meet specific testing needs.
In conclusion, Precipio Inc. is a dynamic diagnostic company that specializes in providing accurate and reliable diagnostic solutions to the healthcare industry. With its advanced technologies, experienced team, and comprehensive range of services, Precipio is dedicated to improving patient care and outcomes through precise and timely diagnostics.
Precipio Inc. offers a wide range of diagnostic tests and services, including cytology, molecular diagnostics, and hematology. The company's proprietary technologies and methodologies allow for fast and precise results, enabling healthcare providers to make informed decisions for patient care.
One of Precipio's key offerings is its cytology services. Cytology is the study of cells to diagnose diseases, and Precipio provides comprehensive cytology testing for various conditions such as cancers, infections, and autoimmune disorders. The company's team of experienced pathologists and laboratory scientists analyze samples using advanced techniques, ensuring accurate and timely results.
In addition to cytology, Precipio specializes in molecular diagnostics, which involves analyzing DNA and RNA to detect genetic and infectious diseases. By utilizing cutting-edge molecular techniques, the company can identify specific genetic mutations, viruses, and bacteria, aiding doctors in making personalized treatment decisions for patients.
Furthermore, Precipio offers hematology testing services, which focus on analyzing blood samples to diagnose and monitor blood-related disorders like anemia, leukemia, and blood clotting disorders. The company's state-of-the-art equipment and skilled laboratory personnel ensure precise and efficient testing, allowing for prompt diagnosis and appropriate treatment.
To support its diagnostic offerings, Precipio has developed a proprietary software platform called HemeScreen. This cloud-based platform integrates with laboratory information systems and supports the entire diagnostic process, from sample collection to reporting. HemeScreen enhances workflow efficiency, minimizes errors, and provides real-time communication between healthcare providers and laboratory personnel.
Precipio also collaborates with healthcare partners, including hospitals, medical centers, and pharmaceutical companies, to develop customized diagnostic solutions. The company's expertise in molecular diagnostics and cytology enables it to offer a range of services tailored to meet specific testing needs.
In conclusion, Precipio Inc. is a dynamic diagnostic company that specializes in providing accurate and reliable diagnostic solutions to the healthcare industry. With its advanced technologies, experienced team, and comprehensive range of services, Precipio is dedicated to improving patient care and outcomes through precise and timely diagnostics.
Precipio Inc. is a biotechnology company that specializes in developing innovative solutions for cancer diagnostics and therapeutic products. The company primarily focuses on offering advanced products and services that leverage its proprietary technologies to improve cancer detection, treatment, and management. Below is an extensive description of the segments, products, and services that Precipio Inc. provides:
Segments
1. Diagnostic Services:
- Precipios diagnostic services aim to enhance the accuracy and reliability of cancer detection. They emphasize molecular biology techniques that provide insights into the genetic mutations associated with specific cancer types.
- The diagnostic offerings typically include next-generation sequencing (NGS), which analyzes multiple genes simultaneously, aiding in identifying relevant mutations that may influence treatment decisions.
2. Therapeutic Services:
- This segment focuses on personalized medicine, where treatments are tailored to the individual patients genetic profile. Precipio aims to provide information on actionable mutations that can guide treatment decisions and enhance therapeutic outcomes.
- The company emphasizes collaborations with pharmaceutical partners to streamline the development of targeted therapies based on the genetic insights garnered through its diagnostic services.
3. Bioinformatics and Data Analytics:
- Precipio incorporates advanced bioinformatics and data analytics in its processes to interpret complex genetic data. This segment plays a crucial role in translating test results into clinically relevant information that can guide healthcare providers in their treatment strategies.
- The company invests in developing proprietary algorithms to enhance the analysis and interpretation of genomic data, enabling quicker turnaround times on diagnostic results.
Products
1. Precipio Lab Services:
- OncoReveal™: A comprehensive liquid biopsy testing solution that detects genetic mutations in circulating tumor DNA (ctDNA). This product is designed for patients who may not be eligible for traditional tissue biopsies.
- Iris™: A unique genetic testing platform that provides extensive panels for various cancers, offering physicians insights into the genetic makeup of a patients tumor. This product is crucial for personalized treatment planning.
- HemeScreen™: Specifically designed for hematological malignancies, this panel tests for mutations in genes commonly associated with blood cancers, providing critical information for diagnosis and treatment decisions.
2. Therapeutic Monitoring Tools:
- Precipio offers solutions that enable healthcare providers to monitor the effectiveness of treatment regimens. These tools analyze serial samples from patients to assess changes in genetic mutations, providing insights into disease progression or response to therapy.
3. Educational and Training Resources:
- The company provides resources aimed at educating healthcare professionals about the importance of personalized medicine and the nuances of genetic testing. This includes webinars, workshops, and access to proprietary research findings.
Services
1. Consultation Services:
- Precipio offers consulting to healthcare providers, helping them interpret genetic test results and make informed treatment decisions based on the insights gleaned from these diagnostics.
2. Partnerships with Healthcare Institutions:
- The company collaborates with hospitals, clinics, and research institutions to integrate its diagnostic products into clinical workflows, facilitating broader access to advanced cancer diagnostics.
3. Research and Development:
- Precipio engages in ongoing R&D to continually improve its product offerings and develop new tests that address emerging needs in cancer diagnostics and treatment.
- The company aims to stay at the forefront of technological advancements in genomics and precision medicine.
4. Regulatory Support:
- Understanding the complex landscape of healthcare regulation, Precipio provides assistance to its partners in navigating the regulatory aspects necessary for the implementation of its products in clinical settings.
In summary, Precipio Inc. operates in dynamic segments encompassing diagnostic services, therapeutic monitoring, and bioinformatics, offering a suite of advanced products focused on improving cancer detection and treatment. Their approach aims to integrate cutting-edge technology with personalized medicine, thereby providing healthcare professionals with critical tools to enhance patient outcomes in oncology.
Segments
1. Diagnostic Services:
- Precipios diagnostic services aim to enhance the accuracy and reliability of cancer detection. They emphasize molecular biology techniques that provide insights into the genetic mutations associated with specific cancer types.
- The diagnostic offerings typically include next-generation sequencing (NGS), which analyzes multiple genes simultaneously, aiding in identifying relevant mutations that may influence treatment decisions.
2. Therapeutic Services:
- This segment focuses on personalized medicine, where treatments are tailored to the individual patients genetic profile. Precipio aims to provide information on actionable mutations that can guide treatment decisions and enhance therapeutic outcomes.
- The company emphasizes collaborations with pharmaceutical partners to streamline the development of targeted therapies based on the genetic insights garnered through its diagnostic services.
3. Bioinformatics and Data Analytics:
- Precipio incorporates advanced bioinformatics and data analytics in its processes to interpret complex genetic data. This segment plays a crucial role in translating test results into clinically relevant information that can guide healthcare providers in their treatment strategies.
- The company invests in developing proprietary algorithms to enhance the analysis and interpretation of genomic data, enabling quicker turnaround times on diagnostic results.
Products
1. Precipio Lab Services:
- OncoReveal™: A comprehensive liquid biopsy testing solution that detects genetic mutations in circulating tumor DNA (ctDNA). This product is designed for patients who may not be eligible for traditional tissue biopsies.
- Iris™: A unique genetic testing platform that provides extensive panels for various cancers, offering physicians insights into the genetic makeup of a patients tumor. This product is crucial for personalized treatment planning.
- HemeScreen™: Specifically designed for hematological malignancies, this panel tests for mutations in genes commonly associated with blood cancers, providing critical information for diagnosis and treatment decisions.
2. Therapeutic Monitoring Tools:
- Precipio offers solutions that enable healthcare providers to monitor the effectiveness of treatment regimens. These tools analyze serial samples from patients to assess changes in genetic mutations, providing insights into disease progression or response to therapy.
3. Educational and Training Resources:
- The company provides resources aimed at educating healthcare professionals about the importance of personalized medicine and the nuances of genetic testing. This includes webinars, workshops, and access to proprietary research findings.
Services
1. Consultation Services:
- Precipio offers consulting to healthcare providers, helping them interpret genetic test results and make informed treatment decisions based on the insights gleaned from these diagnostics.
2. Partnerships with Healthcare Institutions:
- The company collaborates with hospitals, clinics, and research institutions to integrate its diagnostic products into clinical workflows, facilitating broader access to advanced cancer diagnostics.
3. Research and Development:
- Precipio engages in ongoing R&D to continually improve its product offerings and develop new tests that address emerging needs in cancer diagnostics and treatment.
- The company aims to stay at the forefront of technological advancements in genomics and precision medicine.
4. Regulatory Support:
- Understanding the complex landscape of healthcare regulation, Precipio provides assistance to its partners in navigating the regulatory aspects necessary for the implementation of its products in clinical settings.
In summary, Precipio Inc. operates in dynamic segments encompassing diagnostic services, therapeutic monitoring, and bioinformatics, offering a suite of advanced products focused on improving cancer detection and treatment. Their approach aims to integrate cutting-edge technology with personalized medicine, thereby providing healthcare professionals with critical tools to enhance patient outcomes in oncology.